Further, they lay the ground to construct a new bispecific immunoconjugate, made up of anti-PD-L1 antibody covalently linked to Gint4.T aptamer, thus optimizing the efficacy of the combination therapy by increasing their co-targeting at the tumor site while dispensing lower doses of either single agents and overcoming the limits related to the rapid clearance of the aptamers. Here, CD274 is linked to neoplasm.